University of Florence-ko ikertzaileekin lankidetzan egindako argitalpenak (20)

2024

  1. Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study

    Leukemia, Vol. 38, Núm. 10, pp. 2259-2265

2023

  1. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy

    Cochrane Database of Systematic Reviews, Vol. 2023, Núm. 3

2022

  1. Current clinical practice for thromboprophylaxis management in patients with Cushing’s syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN)

    Orphanet Journal of Rare Diseases, Vol. 17, Núm. 1

2021

  1. Phosphatidic acid stimulates myoblast proliferation through interaction with lpa1 and lpa2 receptors

    International Journal of Molecular Sciences, Vol. 22, Núm. 3, pp. 1-20

2018

  1. Blau Syndrome–Associated Uveitis: Preliminary Results From an International Prospective Interventional Case Series

    American Journal of Ophthalmology, Vol. 187, pp. 158-166

  2. Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study

    Journal of Huntington's Disease, Vol. 7, Núm. 3, pp. 209-222

2017

  1. Cognitive decline in Huntington's disease expansion gene carriers

    Cortex, Vol. 95, pp. 51-62

  2. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

    Nature Genetics, Vol. 49, Núm. 12, pp. 1767-1778

2016

  1. Off-label use of rituximab for systemic lupus erythematosus in Europe

    Lupus Science and Medicine, Vol. 3, Núm. 1

  2. The Pocketable Electronic Devices in Radiation Oncology (PEDRO) Project: How the Use of Tools in Medical Decision Making is Changing?

    Technology in Cancer Research and Treatment, Vol. 15, Núm. 2, pp. 365-376

2014

  1. Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: An international collaboration

    Pediatric Rheumatology, Vol. 12, Núm. 1

2013

  1. Off-Label Use Of Rituximab For Systemic Lupus Erythematosus in Europe: Limited Use Mostly In Refractory Patients

    ARTHRITIS AND RHEUMATISM

  2. β-defensin genomic copy number does not influence the age of onset in huntington’s disease

    Journal of Huntington's Disease, Vol. 2, Núm. 1, pp. 107-124

2012

  1. Discrepancies in reporting the CAG repeat lengths for Huntington’s disease

    European Journal of Human Genetics, Vol. 20, Núm. 1, pp. 20-26

  2. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

    Human Mutation, Vol. 33, Núm. 4, pp. 690-702

2011

  1. Biologics use in SLE in 23 Centers - Data from the International Registry for Biologics In SLE (IRBIS)

    ARTHRITIS AND RHEUMATISM

  2. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers

    Journal of the National Cancer Institute, Vol. 103, Núm. 2, pp. 105-116

  3. Pregnancy and reproduction in autoimmune rheumatic diseases

    Rheumatology, Vol. 50, Núm. 4, pp. 657-664

2006

  1. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT)

    Annals of the Rheumatic Diseases, Vol. 65, Núm. 10, pp. 1301-1311

  2. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

    Annals of the Rheumatic Diseases, Vol. 65, Núm. 10, pp. 1312-1324